Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist
Authors' conclusion
Ribupatide exhibited a favourable safety and tolerability profile, along with PK properties consistent with once-weekly administration.
Study context
- Population
- Healthy Chinese participants; preclinical: SD rats, cynomolgus monkeys, diet-induced obese (DIO) mice87 completed
- Participants
- 90 participants
- Comparison
- Ribupatide vs placebo
- Outcome
- Safety and tolerability
Methodological detailssingle-ascending dose, multiple-ascending dose, placebo-controlled, randomised
- Single-ascending dose
- Multiple-ascending dose
- Placebo-controlled
- Randomised
Main finding
As reported in the abstract
Serious treatment-emergent adverse events (TEAEs) or deaths
0
Further findings
| Outcome | Ribupatide | Placebo |
|---|---|---|
| Weight change · after four weekly dosesRange across ribupatide groups | mean −4.3 kg (−6.7%) to −7.7 kg (−9.6%) | mean −1.2 kg (−1.4%) |
Pharmacokinetics (PK): mean half-life (multiple-ascending dose (MAD))
- Mean half-life across the dose range
- 7-8 days
FPG · after single and multiple dosing
- FPG decreased dose-dependently after single and multiple dosing
Preclinical pharmacodynamics (PD) in DIO mice · 28 days
- Significantly reduced body weight and cumulative food intake vs vehicle-treated controls
Safety
- Serious TEAEs or deaths
- 0
- All TEAEs mild-to-moderate in severity
Original publication
Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist. Diabetes Obes Metab. Published 20 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →